CRISM Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Bob Young
Chief executive officer
UK£247.9k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 20.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | no data |
| Board average tenure | 8.3yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£2m |
| Mar 31 2024 | n/a | n/a | -UK£2m |
| Dec 31 2023 | UK£248k | UK£248k | -UK£2m |
| Jun 30 2023 | n/a | n/a | -UK£2m |
| Mar 31 2023 | n/a | n/a | -UK£2m |
| Dec 31 2022 | UK£261k | UK£261k | -UK£2m |
| Jun 30 2022 | n/a | n/a | -UK£3m |
| Mar 31 2022 | n/a | n/a | -UK£2m |
| Dec 31 2021 | UK£235k | UK£235k | -UK£1m |
| Jun 30 2021 | n/a | n/a | -UK£667k |
| Mar 31 2021 | n/a | n/a | -UK£1m |
| Dec 31 2020 | UK£231k | UK£231k | -UK£2m |
| Sep 30 2020 | n/a | n/a | -UK£2m |
| Jun 30 2020 | n/a | n/a | -UK£2m |
| Mar 31 2020 | n/a | n/a | -UK£2m |
| Dec 31 2019 | UK£239k | UK£239k | -UK£2m |
| Sep 30 2019 | n/a | n/a | -UK£2m |
| Jun 30 2019 | n/a | n/a | -UK£2m |
| Mar 31 2019 | n/a | n/a | -UK£2m |
| Dec 31 2018 | UK£248k | UK£248k | -UK£3m |
Compensation vs Market: Bob's total compensation ($USD310.43K) is about average for companies of similar size in the UK market ($USD353.92K).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Young (69 yo)
20.3yrs
Tenure
UK£247,880
Compensation
Mr. Robin Jay Young, also known as Bob, has been the Chief Executive Officer of CRISM Therapeutics Corporation (formerly known as Amur Minerals Corporation) since October 15, 2004 and its Executive Directo...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Secretary & Executive Director | 19yrs | UK£247.88k | 0.12% £ 4.4k | |
| Independent Non-Executive Chairman | 19yrs | UK£45.50k | 0.061% £ 2.2k | |
| Independent Non-Executive Director | 8.3yrs | UK£41.57k | 0.053% £ 1.9k | |
| Independent Non-Executive Director | 5.4yrs | UK£39.22k | 0.17% £ 6.0k | |
| Independent Non-Executive Director | less than a year | no data | 0.076% £ 2.7k |
8.3yrs
Average Tenure
64yo
Average Age
Experienced Board: CRTX's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 19:37 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CRISM Therapeutics Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lord Ashbourne | Edison Investment Research |
| Desmond Kilalea | RBC Capital Markets |